RECURRENT OVARIAN CANCER
Clinical trials for RECURRENT OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OVARIAN CANCER trials appear
Sign up with your email to follow new studies for RECURRENT OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat ovarian cancer?
Disease control CompletedThis early-stage study aimed to find out if adding a new drug called LDE225 to standard chemotherapy (paclitaxel) was safe for women with recurrent ovarian cancer that had stopped responding to platinum-based drugs. The main goal was to check for side effects and determine the be…
Matched conditions: RECURRENT OVARIAN CANCER
Phase: PHASE1 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Common heart pill tested as secret weapon against ovarian cancer
Disease control CompletedThis small, early-stage study tested whether adding a common cholesterol-lowering drug (simvastatin) to standard chemotherapy could help slow the progression of recurrent ovarian cancer. It involved 18 women whose cancer had returned but was still sensitive to platinum-based drug…
Matched conditions: RECURRENT OVARIAN CANCER
Phase: EARLY_PHASE1 • Sponsor: Marc Goodman • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New hope for Tough-to-Treat ovarian cancer?
Disease control CompletedThis study tested whether adding a new oral drug called relacorilant to standard chemotherapy (nab-paclitaxel) could better control cancer growth in women with recurrent ovarian, fallopian tube, or primary peritoneal cancer that had stopped responding to platinum-based drugs. It …
Matched conditions: RECURRENT OVARIAN CANCER
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC